Kolexia
Balsat Mizzon Marie Hématologie
Balsat Mizzon Marie
Hématologie
Hôpital Lyon Sud
Pierre-Bénite, France
129 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie-lymphome lymphoblastique à précurseurs B et T Leucémie myéloïde Leucémie aigüe myéloïde Tumeurs hématologiques Leucémie-lymphome lymphoblastique à précurseurs T Leucémie myéloïde chronique BCR-ABL positive Maladie résiduelle Chromosome Philadelphie

Collaborateurs

Voir plus
Labussiere Wallet Helene
Labussiere Wallet Helene
Hôpital Lyon Sud, Pierre-Bénite, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Boissel Nicolas
Boissel Nicolas
Hôpital Saint-Louis, Paris, France
Ducastelle Lepretre Sophie
Ducastelle Lepretre Sophie
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Novartis
26 collaboration(s)
Dernière en 2023
Servier
11 collaboration(s)
Dernière en 2023
Amgen
8 collaboration(s)
Dernière en 2023
Pfizer
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
CAPTiRALL: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Essai Clinique (Assistance publique – Hôpitaux de Paris)   23 février 2024
CML: A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Essai Clinique (Enliven Therapeutics)   09 janvier 2024
Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023
Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL
65th ASH Annual Meeting Abstracts   02 novembre 2023
NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial
65th ASH Annual Meeting Abstracts   02 novembre 2023
How Much Have Post-Transplant Outcomes Improved Since 2000 for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Remission? a Study from the EBMT Acute Leukemia Working Party
65th ASH Annual Meeting Abstracts   02 novembre 2023